Figure 1 depicts the analytic framework for evaluating the off-label use
of rFVIIa. The figure represents the trajectory of a patient who receives
off-label rFVIIa at some point during in-hospital medical care. Possible times
for drug administration include prophylactic, treatment, and end-stage use. The
thick horizontal arrows represent the overlap between the Key Questions (KQs)
addressed by this report and the different types of rFVIIa use described above.
The potential outcomes examined in this report are shown on the right side of
the figure. These cover a range, from indirect outcomes (process/resource use
and intermediate/surrogate outcomes) to direct clinical endpoints (e.g.,
functional outcome, adverse events, or death).

Figure 1Framework for analyzing outcomes for rFVIIa use

From: Methods

Cover of Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care [Internet].
Comparative Effectiveness Reviews, No. 21.
Yank V, Tuohy CV, Logan AC, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.